Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Jiri Bartek"'
Autor:
Anne Kallioniemi, Anna Tervasmäki, Rainer Fagerholm, Jirina Bartkova, Johanna I. Kiiski, Maria Tengström, Kristiina Aittomäki, Tuomo Mantere, Veli-Matti Kosma, Carl Blomqvist, Maral Jamshidi, Liisa M. Pelttari, Katri Pylkäs, Sofia Khan, Heli Nevanlinna, Arto Mannermaa, Jiri Bartek, Robert Winqvist
Publikováno v:
International Journal of Cancer
Breast cancer (BC) is a heterogeneous disease, and different tumor characteristics and genetic variation may affect the clinical outcome. The FANCM c.5101C > T nonsense mutation in the Finnish population associates with increased risk of breast cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::975bf5a4fb2f0abc7e5892a0e6ec3ee0
http://hdl.handle.net/10138/170127
http://hdl.handle.net/10138/170127
Autor:
Päivi Heikkilä, Maral Jamshidi, Johanna Tommiska, Carl Blomqvist, Kenneth Villman, Johanna Mattson, Radek Vrtel, Jirina Bartkova, Kristiina Aittomäki, Jiri Bartek, Dario Greco, Jiri Lukas, Heli Nevanlinna, Rainer Fagerholm
Publikováno v:
Breast Cancer Research and Treatment; Vol 132
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment
NQO1 participates in cellular defense against oxidative stress and regulates apoptosis via p53- and NFκB-mediated pathways. We have previously found that homozygous missense variant NQO1*2 (rs1800566) predicts poor survival among breast cancer patie
Autor:
Heli Nevanlinna, Jiri Bartek
Publikováno v:
Oncogene. 25:5912-5919
Checkpoint kinase 2 (CHEK2, Chk2) emerges as an important signal transducer of cellular responses to DNA damage and a candidate tumor suppressor whose defects contribute to molecular pathogenesis of diverse types of human malignancies, both sporadic
Autor:
Anitta Tamminen, Heli Nevanlinna, Päivi Heikkilä, Jiri Bartek, Jirina Bartkova, Olli-P. Kallioniemi, Kaija Holli, Outi Kilpivaara, Juha Kononen, Carl Blomqvist, Salla Ojala, Pia Vahteristo, Kirsi Syrjäkoski, Hannaleena Eerola, Kristiina Aittomäki
Publikováno v:
The American Journal of Human Genetics. 71(2):432-438
CHEK2 (previously known as “CHK2”) is a cell-cycle–checkpoint kinase that phosphorylates p53 and BRCA1 in response to DNA damage. A protein-truncating mutation, 1100delC in exon 10, which abolishes the kinase function of CHEK2, has been found i
Autor:
Don Weaver, Tuomas Heikkinen, Kristiina Aittomäki, Carl Blomqvist, Jiri Bartek, Päivi Heikkilä, Rainer Fagerholm, Heli Nevanlinna, J Bartkova, K. M. Sprott
Publikováno v:
Annals of Oncology; Vol 24
Background Defective DNA repair is central to the progression and treatment of breast cancer. Immunohistochemically detected DNA repair markers may be good candidates for novel prognostic and predictive factors that could guide the selection of indiv
Autor:
Carl Blomqvist, William E. Pierceall, Jiri Bartek, Heli Nevanlinna, Lakshmi P. Alaparthi, Vivian Villegas-Bergazzi, Jirina Bartkova, David T. Weaver, Jane L. Meyer, K. M. Sprott, Mohammed Al-Adhami, Tuomas Heikkinen, Kristiina Aittomäki, Päivi Heikkilä, Jeffery L. Kutok
Publikováno v:
Human pathology. 43(9)
Tumor biomarkers increasingly provide information for predicting outcomes with chemotherapeutic regimens (personalized medicine). Topo2A is a DNA helicase targeted by anthracyclines, cytotoxic therapeutics used in both adjuvant and palliative treatme
Autor:
Domenico Delia, Paolo Radice, Gaia Roversi, Jiri Bartek, Jirina Bartkova, Simona Frigerio, Bernard Peissel, Daniele Lecis, Siranoush Manoukian
Publikováno v:
Breast cancer research and treatment. 130(1)
CHEK2 gene mutations occur in a subset of patients with familial breast cancer, acting as moderate/low penetrance cancer susceptibility alleles. Although CHEK2 is no longer recognized as a major determinant of the Li-Fraumeni syndrome, a hereditary c
Autor:
Jiri Bartek, M. Coppen, Jonathan Mangion, Sarah Thomas, S. Gray, Gerald Gui, Rosalind A. Eeles, S. Ebbs, John Yarnold, Roger A'Hern, G. Knee, S. Jhavar, Colin Cooper
Publikováno v:
Breast cancer research and treatment. 129(3)
Clonality of multicentric breast cancer has traditionally been difficult to assess. We aimed to assess this using analysis of TP53 status (expression and mutation status). These results were then incorporated into an analysis of prognostic factors in
Autor:
Shridar Ganesan, Maria Thanasoula, Hanneke van der Gulden, Jiri Bartek, Atul Kulkarni, Qifeng Yang, Ronny Drapkin, David J. Adams, Madalena Tarsounas, Peter Bouwman, Carl Blomqvist, Heli Nevanlinna, Johanna Tommiska, Jos Jonkers, Jirina Bartkova, José M. Escandell, Mark Pieterse, Sanne Hiddingh, Amal Aly, Bruce G. Haffty
Publikováno v:
Nature Structural & Molecular Biology; Vol 17
Germ-line mutations in breast cancer 1, early onset (BRCA1) result in predisposition to breast and ovarian cancer. BRCA1-mutated tumors show genomic instability, mainly as a consequence of impaired recombinatorial DNA repair. Here we identify p53-bin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7480cc2a1b27064ed494893233071660
https://hdl.handle.net/1887/139074
https://hdl.handle.net/1887/139074
Autor:
Jiri Bartek, Lenka Oplustilova, Carl Blomqvist, Jiri Lukas, Johanna Tommiska, Martin Mistrik, Jirina Bartkova, Heli Nevanlinna, Anitta Tamminen, Kristiina Aittomäki, Päivi Heikkilä, Kirsimari Aaltonen, Tuomas Heikkinen
Publikováno v:
Molecular oncology. 2(4)
The MRE11, RAD50,andNBS1 genes encode proteins of the MRE11–RAD50–NBS1 (MRN)complex critical for proper maintenance of genomic integrity and tumour suppression;however, the extent and impact of their cancer-predisposing defects, and potentialclin